What is MediPal Holdings Corporation?
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan.
MEPDF · Verdict
Moderate reward · low risk
MEPDF stands out on balance sheet and valuation, but watch the profitability signal.
Based on 88% data coverage
MEPDF · Verdict
Interest covered 10963.0×
Above average
Above average
1% net margin · 7% ROE
Rev +3.7% CAGR · earnings +11.0%
Model-based scoring. For information only — not financial advice.
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprising medical equipment and medical materials, and clinical diagnostic reagents for use from the pre-symptomatic stage; handles PMS services on contract for manufacturers; and invests in orphan drugs and other products. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 3.89B, and a P/E ratio of 15.0x.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.